Rola eotaksyn w patofizjologii astmy

Paplińska, Magdalena; Grubek-Jaworska, H; Chazan, Ryszarda

doi:10.5603/arm.27997

Cited by 8 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is likely due to the reduction in IL-4, IL-13, and VEGF, which facilitates transmigration of circulating eosinophils into the asthmatic lungs (36,37). Concomitantly, normalization of the CCL11 level by the therapy likely contributed to blockade of eosinophil recruitment, given that the chemokine serves as a primary chemoattractant to eosinophils (37,38). It has been previously reported that eosinophil-deficient mice are notably protected from airway collagen deposition and smooth muscle accumulation despite the challenge by OVA (39).…”

Section: Discussionmentioning

confidence: 99%

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma

et al. 2020

View full text Add to dashboard Cite

Despite long-standing efforts to enhance care for chronic asthma, symptomatic treatments remain the only option to manage this highly prevalent and debilitating disease. We demonstrate that key pathology of allergic asthma can be almost completely resolved in a therapeutic manner by inhaled gene therapy. After the disease was fully and stably established, we treated mice intratracheally with a single dose of thymulin-expressing plasmids delivered via nanoparticles engineered to have a unique ability to penetrate the airway mucus barrier. Twenty days after the treatment, we found that all key pathologic features found in the asthmatic lung, including chronic inflammation, pulmonary fibrosis, and mechanical dysregulation, were normalized. We conducted tissue- and cell-based analyses to confirm that the therapeutic intervention was mediated comprehensively by anti-inflammatory and antifibrotic effects of the therapy. We believe that our findings open a new avenue for clinical development of therapeutically effective gene therapy for chronic asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma

et al. 2020

View full text Add to dashboard Cite

show abstract

Intranasal Curcumin Inhibits Pulmonary Fibrosis by Modulating Matrix Metalloproteinase-9 (MMP-9) in Ovalbumin-Induced Chronic Asthma

Chauhan¹,

Dash

Singh³

2016

Inflammation

View full text Add to dashboard Cite

Pulmonary fibrosis is associated with irreversible, or partially reversible, airflow obstruction and ultimately unresponsiveness to asthma therapies such as corticosteroids. Intranasal curcumin, an anti-inflammatory molecule, has been found effective in allergic asthma. To study the effect of intranasal curcumin on airway remodeling and fibrosis in murine model of chronic asthma, BALB/c mice were sensitized to ovalbumin (OVA) and exposed to OVA aerosol (2%) from day 21 (after sensitization) for 5 weeks (twice/week). Curcumin (intranasal) was administered during the OVA aerosol challenge. Mice exposed to OVA developed inflammation dominated by eosinophils which lead to fibrosis and airway remodeling. Intranasal administration of curcumin significantly inhibited airway inflammation and pulmonary fibrosis, where MMP-9 activities were decreased along with α-smooth muscle actin (α-SMA), MMP-9, TIMP-1, and eotaxin expressions. These results suggest that intranasal curcumin regulates airway inflammation and remodeling in chronic asthma.

show abstract